Complex karyotype and non‐ BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia

Summary We retrospectively analysed 646 chronic lymphocytic leukaemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana‐Farber Cancer Institute from 2014 to 2023. Among them, 122 underwent next‐generation sequencing (NGS) during or at the next office visit after BTKi therapy (ibrutinib [IBR], 85; acalabrutinib [ACA], 23; pirtobrutinib [PIR], 9; vecabrutinib [VEC], 1; zanubrutinib [ZANU], 4). Compared with the non‐progressor (NP) group ( N = 75), patients with NGS at progression (PD group, N = 47) more commonly had 17p deletion, complex karyotype, heavier prior treatment exposure and prior exposure to a different BTKi before the current regimen. We found 321 mutations in 67 genes, with more mutations in the PD group (231 mutations), including 39 BTK ( BTK C481S/F/R/Y, L528W and T474I/L) and 26 phospholipase C gamma 2 ( PLCG2 ) mutations. Among the 12 PD patients with serial samples, all acquired new or expanded BTK or TP53 mutations. Complex karyotype, specifically 8p loss, was significantly enriched in the PD group. tumour protein p53 ( TP53 ), splicing factor 3b subunit 1 ( SF3B1 ), protein phosphatase, Mg 2 + /Mn 2 + dependent 1D ( PPM1D ) and notch receptor 2 ( NOTCH2 ) mutations were also significantly more prevalent in the PD group (all p < 0.05). Additionally, pathogenic mitogen‐activated protein kinase (MAPK) pathway mutations trended more common and had higher variant allele frequencies (VAFs) in the PD group ( p = 0.047). These findings suggest that TP53 aberration and 8p‐loss‐associated complex karyotype, as well as several non‐BTK driver mutations, are enriched in BTKi‐resistant patients.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-11-16
DOI
https://doi.org/10.1111/bjh.70925
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Complex karyotype and non‐ BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia

Rayan Fardoun, Stacey M. Fernandes, Uday Aditya Sarkar, Mariia Mikhaleva et al.
British Journal of Haematology
Chronic Lymphocytic Leukemia Research
article

Complex karyotype and non‐ BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia

Rayan Fardoun, Stacey M. Fernandes, Uday Aditya Sarkar, Mariia Mikhaleva, Jennifer R. Brown, Aishath S. Naeem, Samantha J. Shupe, Kiyomi Mashima, Binu Kandathilparambil Sasi, Inhye E. Ahn, Saurabh Yadav, Matthew Steven Davids, John‐Hanson Machado, Stephen P. Martindale, Roberta Santos Azevedo, Ava Bidgoli, Paulina Predko, Colin Mcnulty, Xinhao Sun, Paige R. Fitzgerald, Ava M. Kominski
article en

Abstract

Summary We retrospectively analysed 646 chronic lymphocytic leukaemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana‐Farber Cancer Institute from 2014 to 2023. Among them, 122 underwent next‐generation sequencing (NGS) during or at the next office visit after BTKi therapy (ibrutinib [IBR], 85; acalabrutinib [ACA], 23; pirtobrutinib [PIR], 9; vecabrutinib [VEC], 1; zanubrutinib [ZANU], 4). Compared with the non‐progressor (NP) group ( N = 75), patients with NGS at progression (PD group, N = 47) more commonly had 17p deletion, complex karyotype, heavier prior treatment exposure and prior exposure to a different BTKi before the current regimen. We found 321 mutations in 67 genes, with more mutations in the PD group (231 mutations), including 39 BTK ( BTK C481S/F/R/Y, L528W and T474I/L) and 26 phospholipase C gamma 2 ( PLCG2 ) mutations. Among the 12 PD patients with serial samples, all acquired new or expanded BTK or TP53 mutations. Complex karyotype, specifically 8p loss, was significantly enriched in the PD group. tumour protein p53 ( TP53 ), splicing factor 3b subunit 1 ( SF3B1 ), protein phosphatase, Mg 2 + /Mn 2 + dependent 1D ( PPM1D ) and notch receptor 2 ( NOTCH2 ) mutations were also significantly more prevalent in the PD group (all p < 0.05). Additionally, pathogenic mitogen‐activated protein kinase (MAPK) pathway mutations trended more common and had higher variant allele frequencies (VAFs) in the PD group ( p = 0.047). These findings suggest that TP53 aberration and 8p‐loss‐associated complex karyotype, as well as several non‐BTK driver mutations, are enriched in BTKi‐resistant patients.

British Journal of Haematology
Harvard University (US), Dana-Farber Cancer Institute (US)
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon